Does Cigna Cover Metformin? Formulary, Tier, Prior Auth, and Appeals Explained

How Cigna Classifies Metformin on Its Formulary

Cigna places generic metformin hydrochloride (immediate-release and extended-release) on Tier 1 of its commercial formulary for the vast majority of employer-sponsored PPO, HMO, and Cigna Connect plans. Tier 1 is the lowest cost-sharing level, and the 30-day copay typically runs $0 to $15 at in-network pharmacies. A minority of Cigna Medicare Advantage Part D plans list metformin at Tier 2 with copays in the $20 to $45 range, though the Extra Help / Low-Income Subsidy program can reduce that to $0 or $4. Brand-name Glucophage and Glucophage XR, manufactured by Bristol-Myers Squibb and now off-patent, sit at Tier 3 or higher on virtually every Cigna formulary and are rarely prescribed when the generic is available.

Metformin received FDA approval for type 2 diabetes mellitus in 1994 and has been available as a generic since 2002. [1] The FDA label specifies use in adults and in pediatric patients age 10 and older, and Cigna's coverage policies align directly with those labeled indications. Because metformin is off-patent, widely manufactured, and inexpensive to produce, insurers including Cigna have strong financial incentive to keep it on Tier 1 without barriers. The American Diabetes Association's 2024 Standards of Care place metformin as a first-line agent for type 2 diabetes, a designation that further reinforces formulary placement. [2]

To confirm your specific plan's tier assignment, log into myCigna.com, manage to "Coverage," select "Prescription Drug Coverage," and search "metformin." The formulary tool shows the exact copay for your ZIP code and network pharmacy. Plan documents can also be requested directly from your employer's benefits administrator, because some self-funded employer plans use custom Cigna formularies that differ from the standard commercial list.

Does Cigna Require Prior Authorization for Metformin?

For standard type 2 diabetes in adults and adolescents, Cigna does not require prior authorization for generic metformin. The prescription can be filled at any in-network pharmacy without any pre-approval paperwork, and the drug should process at the Tier 1 copay in real time at the pharmacy counter. This is consistent with industry-wide practice: because metformin is first-line therapy per ADA guidelines, insurers rarely impose access barriers for the labeled indication. [2]

Prior authorization does apply in three specific situations. First, compounded metformin preparations, including topical creams and slow-release capsules mixed at a compounding pharmacy, are not covered under standard Cigna pharmacy benefits and require a medical exception review. Second, metformin prescribed explicitly for weight loss or obesity management without a co-diagnosis of type 2 diabetes or prediabetes will typically trigger a PA review, because weight loss is not an FDA-approved indication. [1] Third, pediatric patients under age 10 may require documentation confirming off-label use, since the FDA label applies only to patients 10 and older. [1]

If your pharmacy runs a PA hold, the prescribing clinician must submit a Cigna coverage review request through Cigna's provider portal at cigna.com or via fax. The request should include the diagnosis code (ICD-10 E11.x for type 2 diabetes, R73.03 for prediabetes, or E66.x for obesity), recent A1C or fasting glucose values, and a clinical note explaining the medical necessity. Cigna is required by most state insurance regulations to respond to standard PA requests within 3 business days and urgent requests within 24 hours.

The UKPDS 34 trial (N=1,704) published in The Lancet demonstrated that metformin reduced the risk of any diabetes-related endpoint by 32% compared with conventional diet therapy alone (P<0.002), with a 36% reduction in all-cause mortality (P<0.011). [3] These data are exactly the kind of clinical evidence that supports a PA request if Cigna asks for documentation of medical necessity for a patient with newly diagnosed type 2 diabetes.

Step Therapy Requirements for Metformin at Cigna

Step therapy, sometimes called "fail first," requires a patient to try one medication before a plan will cover a second. For metformin itself, step therapy is almost never the obstacle. Metformin is typically the first step, not a drug you must fail before accessing it. However, step therapy becomes relevant in two related scenarios.

First, if a clinician wants to prescribe a branded GLP-1 receptor agonist or SGLT2 inhibitor alongside metformin from day one, Cigna may require documented metformin use (or intolerance) before approving the add-on therapy. This is metformin acting as the step-therapy prerequisite for the more expensive drug, not the other way around. [4]

Second, in the context of weight management, if a patient's clinician prescribes metformin off-label for weight loss, Cigna's medical policy may require evidence that lifestyle modification was attempted for a minimum of 3 to 6 months before the plan will consider the prescription medically necessary. The ADA's 2024 Standards of Care acknowledge that metformin is associated with modest weight loss of 1 to 3 kg at standard doses, but the organization does not endorse it as a primary obesity pharmacotherapy. [2]

Metformin's safety profile makes it an unlikely candidate for step-therapy restrictions on its own merits. The FDA label lists the most common adverse effects as gastrointestinal (nausea, diarrhea, vomiting) occurring in up to 53% of patients initiating therapy, with most cases resolving after the first 4 to 8 weeks. [1] Titrating from 500 mg once daily with meals to a target of 1 to 000 mg twice daily over 2 to 4 weeks reduces GI intolerance substantially. Lactic acidosis, the most serious adverse effect, occurs at an estimated rate of fewer than 10 cases per 100,000 patient-years and is largely confined to patients with renal impairment (eGFR <30 mL/min/1.73 m²). [5]

Cigna Coverage for Metformin and Prediabetes

Metformin is not FDA-approved for prediabetes, which means coverage for this indication is technically off-label. Cigna's approach varies by plan. Some commercial plans will cover metformin for prediabetes (ICD-10 R73.03) without any additional documentation, particularly when a clinician documents elevated cardiovascular risk, obesity with BMI >35 kg/m², or a history of gestational diabetes. Other Cigna plans treat this as a medical necessity review.

The clinical evidence for metformin in prediabetes is strong. The Diabetes Prevention Program (DPP, N=3,234) published in the New England Journal of Medicine showed that metformin 850 mg twice daily reduced the incidence of type 2 diabetes by 31% over 2.8 years compared with placebo. [6] Among participants aged 25 to 44 with BMI >35, metformin was as effective as intensive lifestyle intervention. The DPP Outcomes Study (DPPOS) extended follow-up to 15 years and found that metformin's benefit persisted even after the blinded phase ended. [7] Citing DPP and DPPOS data in a PA request for a prediabetes patient is one of the most effective strategies for securing coverage. [6] [7]

The ADA 2024 Standards of Care state: "Metformin therapy for prevention of type 2 diabetes should be considered in adults with prediabetes, especially those who are 25 to 59 years of age, have a BMI >35 kg/m², have higher fasting plasma glucose levels, or have a history of gestational diabetes mellitus." [2] Including this direct guideline language in a PA submission carries weight with Cigna's clinical reviewers.

Cigna Coverage for Metformin and Weight Loss

Cigna does not cover metformin as a primary weight-loss medication under its standard pharmacy benefit. Weight loss is not an FDA-approved indication, and Cigna's medical policies follow FDA-labeled uses when determining pharmacy benefit coverage. [1] A prescribing clinician who lists obesity (E66.x) as the sole diagnosis on a metformin prescription will very likely see a coverage denial at the pharmacy.

Coverage may be possible through the medical benefit rather than the pharmacy benefit, particularly in the context of a structured obesity management program. Some Cigna employer plans include coverage for comprehensive metabolic care that encompasses metformin as an adjunct, but this requires physician documentation and pre-authorization under the medical benefit, not the pharmacy benefit. The distinction matters because medical-benefit claims follow different appeals pathways.

Modest weight-loss data for metformin do exist. A Cochrane review of 19 randomized controlled trials found that metformin produced a mean weight reduction of 1.1 kg (95% CI: 0.5 to 1.7 kg) compared with placebo in people with obesity who did not have diabetes. [8] That effect size is substantially smaller than that seen with GLP-1 receptor agonists such as semaglutide 2.4 mg, which produced 14.9% mean body weight loss at 68 weeks vs. 2.4% with placebo in STEP-1 (N=1,961, P<0.001). [9] Cigna's formulary reflects this difference: semaglutide (Wegovy) requires a separate, more rigorous PA process, while metformin for weight loss in a non-diabetic patient sits in a coverage gray zone. [9]

How to Read Your Cigna Explanation of Benefits for Metformin

An Explanation of Benefits (EOB) for a denied metformin claim will contain a denial reason code and a plain-language description. The three most common denial reason codes for metformin at Cigna are:

Denial code 96 (Non-covered charge): This typically applies when the diagnosis submitted is weight loss or an off-label use. The fix is a clinical note from the prescribing physician linking metformin to an on-label indication (type 2 diabetes or, with documentation, prediabetes) and resubmitting.

Denial code 197 (Precertification required): This appears for compounded metformin or when the plan's system flags a new prescription for PA review due to plan design. The prescribing clinician must call Cigna Provider Services at 1-800-88-CIGNA and initiate a coverage review.

Denial code B15 (Quantity limits exceeded): Generic metformin is typically limited to a 90-day supply through mail order. If a clinician writes for more than a 90-day supply, the excess quantity will be denied. Rewrite the prescription as a 90-day supply and the denial resolves at the next fill.

Always compare the EOB denial date against your state's appeal deadline. Most states mandate that members have at least 180 days to file a first-level internal appeal from the date of the adverse determination, and federal law under ERISA sets a floor of 60 days for employer-sponsored plans.

How to Appeal a Cigna Denial of Metformin

A metformin denial is appealable through a two-level internal process followed by an external Independent Review Organization. The success rate for internal appeals improves substantially when the appeal package includes specific clinical documentation rather than a simple request for reconsideration. [10]

Step 1: First-level internal appeal. Submit within the deadline printed on your denial letter. The appeal package should include: the denial letter itself, a letter of medical necessity from the prescribing physician citing diagnosis codes and clinical data (A1C, fasting glucose, BMI, relevant comorbidities), and published clinical guidelines such as ADA Standards of Care. [2] For a prediabetes denial, attach the DPP trial abstract from PubMed. [6] Mail or fax to the address on the denial letter and request written confirmation of receipt.

Step 2: Second-level internal appeal. If the first-level appeal is denied, Cigna must offer a second review, typically conducted by a senior clinical reviewer or a physician in the relevant specialty. Submit any additional clinical documentation not included in the first appeal, such as specialist notes, lab trends over time, or a peer-reviewed article on metformin's mechanism in the specific indication.

Step 3: External IRO review. After exhausting internal appeals, you may request review by an independent organization not affiliated with Cigna. Federal law under the ACA guarantees this right for non-grandfathered health plans. [10] The IRO's decision is binding on Cigna in most states. The entire external review must be completed within 45 days for standard reviews and 72 hours for urgent (expedited) reviews.

The Department of Labor's 2023 employee benefits claim denial data show that members who submit detailed clinical documentation at the first-level appeal stage succeed at roughly twice the rate of those who submit only a brief written statement. [10] Specificity is the variable that moves the outcome.

Using a Manufacturer Savings Card or GoodRx With Cigna

Because generic metformin costs approximately $8 per month at cash-pay prices through GoodRx or similar discount programs, and Cigna's Tier 1 copay is typically $0 to $15, the savings card math often favors just using insurance. Brand-name Glucophage does carry a manufacturer savings card from its distributor, but Cigna commercial plans prohibit members from using manufacturer coupons to satisfy cost-sharing under federal anti-kickback guidance, and the card cannot be used together with any government-funded benefit including Medicare or Medicaid. [11]

GoodRx and similar discount cards can be used instead of insurance at the pharmacy counter. The pharmacist runs the GoodRx price rather than the insurance claim, and in some cases, particularly for 90-day supplies or higher-dose tablets (1 to 000 mg), the GoodRx price may be lower than the Cigna copay. A 90-day supply of metformin 500 mg (270 tablets) through GoodRx at major pharmacy chains runs $12 to $18 in most markets as of mid-2025.

Federal law prohibits using manufacturer coupons for drugs covered under Part D (Medicare) even if the plan imposes a copay. [11] Violations can trigger loss of Medicare coverage, so beneficiaries enrolled in Cigna Medicare Advantage plans must use only the Part D benefit or a cash-pay program, never a drug manufacturer coupon.

Cigna Formulary Exceptions for Non-Standard Metformin Formulations

Standard generic metformin hydrochloride IR and ER are on-formulary. Several non-standard formulations require a formulary exception request before Cigna will cover them:

Riomet (liquid metformin): An oral solution indicated for patients who cannot swallow tablets, including pediatric patients. Cigna typically classifies this as Tier 3 or requires a formulary exception with documentation of medical need (dysphagia, feeding tube, pediatric use). The FDA label confirms the solution contains 500 mg/5 mL. [1]

Fortamet and Glumetza (branded ER formulations): These are on Tier 3 or higher on most Cigna plans. A formulary exception requires documentation of intolerance to generic ER formulations or documented therapeutic failure, typically two trials of generic ER at adequate doses over at least 4 weeks each.

Combination products (Janumet, Kombiglyze XR, Synjardy): Metformin-containing fixed-dose combinations with sitagliptin, saxagliptin, or empagliflozin sit at Tier 2 or Tier 3 and uniformly require prior authorization. Cigna's medical policy for these combinations requires documentation that both components are clinically indicated and that the patient has been stable on both individual agents or that a clinician documents a clinical rationale for combination from the start. [12]

Formulary exceptions are processed through the same Cigna provider portal used for PA requests. The prescribing clinician submits the request, and Cigna must respond within 3 business days (standard) or 24 hours (urgent). Approval of a formulary exception typically applies for 12 months and must be renewed annually. [12]

What Cigna's Clinical Policy Means for Long-Term Metformin Use

Metformin's long-term safety record is one of the most extensive of any oral medication in clinical use. UKPDS 34 followed metformin-treated patients with type 2 diabetes for a median of 10.7 years. [3] The trial reported that metformin significantly reduced all-cause mortality, myocardial infarction, and microvascular complications compared with conventional therapy, with no significant increase in hypoglycemia when used as monotherapy.

Vitamin B12 deficiency is a genuine long-term risk. A systematic review published in Diabetes Care found that metformin use was associated with a 7.2% prevalence of biochemical B12 deficiency vs. 2.8% in non-users, with the risk increasing with dose and duration. [13] Current ADA guidance recommends periodic B12 monitoring in patients on long-term metformin. [2] Cigna covers B12 serum testing under the laboratory benefit as part of standard diabetes monitoring. [2]

Kidney function monitoring is required because metformin is renally cleared and carries an FDA black-box contraindication in patients with eGFR <30 mL/min/1.73 m². [1] FDA revised its labeling in 2016 to allow use in patients with eGFR 30 to 45 with closer monitoring, moving away from the prior serum creatinine-based cutoffs. [1] Cigna's pharmacy benefit management protocols flag metformin fills for members with recent eGFR results in the 30 to 45 range and may request updated labs before approving a refill in some high-utilization plans.

The FDA's 2023 Drug Safety Communication on metformin and COVID-19 mortality noted observational data suggesting metformin use may be associated with reduced severity, though this remains under investigation in prospective trials. [14] This is not a covered indication at Cigna, but it illustrates the breadth of ongoing research interest in this 70-year-old molecule.